Basel, Switzerland-based Basilea and its development partner, Johnson & Johnson, disclosed recently they had filed a new drug application for Ceftobiprole, a broad-spectrum cephalosporin antibiotic, for treatment of complicated skin and skin structure infection (cSSSI). A U.S. drug launch could follow early next year. (BioWorld International)

Partners Elan Corp. plc and Wyeth said they plan to begin Phase III testing of their lead immunotherapeutic candidate bapineuzumab (AAB-001) for mild to moderate Alzheimer's disease in the second half of this year, boosting excitement around the disease-modifying agent. (BioWorld Today)